Crohn's Disease in
the Clinical Setting
About CIMZIA®
Dosing and
Administration
Clinical Trials Overview
Patient Support
Safety Information
Resources
For Patients & Caregivers
Prescribing Information

This site is intended for
US residents.

Disease Severity

Generally, the management of Crohn's Disease (CD) is based on the location and severity of the disease and its complications.1 There is no established checklist for determining the severity of CD, but classifications of disease severity as determined by the American College of Gastroenterology may help guide physicians in choosing various medical treatments.1

American College of Gastroenterology Practice Guidelines1

Reference:

  1. Hanauer SB, Sandborn W, and The Practice Parameters Committee of the American College of Gastroenterology. Practice Guidelines: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2001;96:635-643.

CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.
For more information 1.866.4.CIMZIA
CIMZIA